XYXiao Yi

Xiao Yi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiao Yi has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Chen

    Translational Medicine Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China

    2 shared publications
  • Haoyuan Jiang

    Department of Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China

    2 shared publications
  • Honglei Zhu

    Department of Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China

    2 shared publications
  • Huayan Li

    Department of Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China

    2 shared publications
  • Kunjie Gao

    Department of Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China

    2 shared publications
  • Qian Wang

    Translational Medicine Research Center, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China

    2 shared publications

Latest Publications

  • Open Access

    Biomimetic nanostructural materials based on placental amniotic membrane-derived nanofibers for self-healing and anti-adhesion during cesarean section

    by Honglei Zhu, Fenghua Liu, Yuru Liao, Huayan Li, Kunjie Gao, Xiaomei Liang, Haoyuan Jiang, Feng Chen, Jianwei Wu, Qian Wang, et al.


  • Opportunities and Perspectives for Three Dimensional Culture of Mesenchymal Stem Cell-Derived Exosomes

    by Guanyi Lin, Wennuo Pan, Yingde He, Xiao Yi, Pengyu Zhou, Jun Lu

    Exosomes are nanosized extracellular vesicles (EVs) that participate in intercellular communication through surface proteins and the delivery of internal cargo. The exosomes have gained attention for their potential as disease biomarkers and therapeutic agents. The therapeutic ability of exosomes has been verified by copious previous studies. Effective methods for extensive clinical applications are being researched for exosome-based regenerative therapies, including the application of 3D cultures to enhance exosome production and secretion which can resolve limited exosome secretory from the parent cells. Cell culture has emerged as a crucial approach for biomedical research because of its many benefits. Both well-established continuous cell lines and primary cell cultures continue to be invaluable for basic research and clinical application. Previous studies have shown that three-dimensional cultured exosomes (3D-Exo) improve therapeutic properties and yields compared to traditional culture systems. Since the majority of studies have focused on exosomes derived from mesenchymal stem cells (MSC-Exo), this review will also concentrate on MSC-Exo. In this review, we will summarize the advantages of 3D-Exo and introduce the 3D culture system and methods of exosome isolation, providing scientific strategies for the diagnosis, treatment, and prognosis of a wide variety of diseases.


  • Open Access

    Cervical extracellular matrix hydrogel optimizes tumor heterogeneity of cervical squamous cell carcinoma organoids

    by Haonan Song, Haoyuan Jiang, Weichu Hu, Yan Hai, Yihuan Cai, Hu Li, Yuru Liao, Yi Huang, Xiaogang Lv, Yefei Zhang, et al.

    Cervical cancer, primarily squamous cell carcinoma, is the most prevalent gynecologic malignancy. Organoids can mimic tumor development in vitro, but current Matrigel inaccurately replicates the tissue-specific microenvironment. This limitation compromises the accurate representation of tumor heterogeneity. We collected para-cancerous cervical tissues from patients diagnosed with cervical squamous cell carcinoma (CSCC) and prepared uterine cervix extracellular matrix (UCEM) hydrogels. Proteomic analysis of UCEM identified several tissue-specific signaling pathways including human papillomavirus, phosphatidylinositol 3-kinase–AKT, and extracellular matrix receptor. Secreted proteins like FLNA, MYH9, HSPA8, and EEF1A1 were present, indicating UCEM successfully maintained cervical proteins. UCEM provided a tailored microenvironment for CSCC organoids, enabling formation and growth while preserving tumorigenic potential. RNA sequencing showed UCEM-organoids exhibited greater similarity to native CSCC and reflected tumor heterogeneity by exhibiting CSCC-associated signaling pathways including virus protein-cytokine, nuclear factor κB, tumor necrosis factor, and oncogenes EGR1, FPR1, and IFI6. Moreover, UCEM-organoids developed chemotherapy resistance. Our research provides insights into advanced organoid technology through native matrix hydrogels.


  • Chorionic villi-derived nanofibers enhanced mesenchymal stem cell extracellular vesicle secretion and bioactivity for endometrium regeneration toward intrauterine adhesion treatment

    by Honglei Zhu, Huayan Li, Kunjie Gao, Yi Huang, Yuru Liao, Weichu Hu, Feng Chen, Haoyuan Jiang, Xiaomei Liang, Haonan Song, et al.


  • Open Access

    A simple and efficient strategy for cell‐based and cell‐free‐based therapies in acute liver failure: hUCMSCs bioartificial liver

    by Lei Feng, Yi Wang, Yu Fu, Adilijiang Yimamu, Zeyi Guo, Chenjie Zhou, Shao Li, Linya Zhang, Jiasheng Qin, Shusong Liu, et al.

    Acute liver failure (ALF) is a life‐threatening condition. Cell‐based and cell‐free‐based therapies have proven to be effective in treating ALF; however, their clinical application is limited by cell tumorigenicity and extracellular vesicle (EV) isolation in large doses. Here, we explored the effectiveness and mechanism of umbilical cord mesenchymal stem cells (hUCMSCs)‐based bioartificial liver (hUCMSC‐BAL), which is a simple and efficient strategy for ALF. D‐galactosamine‐based pig and mouse ALF models were used to explore the effectiveness of hUCMSC‐BAL and hUCMSC‐sEV therapies. Furthermore, high‐throughput sequencing, miRNA transcriptome analysis, and western blot were performed to clarify whether the miR‐139‐5p/PDE4D axis plays a critical role in the ALF model in vivo and in vitro. hUCMSC‐BAL significantly reduced inflammatory responses and cell apoptosis. hUCMSC‐sEV significantly improved liver function in ALF mice and enhanced the regeneration of liver cells. Furthermore, hUCMSC‐sEV miRNA transcriptome analysis showed that miR‐139‐5p had the highest expression and that PDE4D was one of its main target genes. The sEV miR‐139‐5p/PDE4D axis played a role in the treatment of ALF by inhibiting cell apoptosis. Our data indicate that hUCMSC‐BAL can inhibit cytokine storms and cell apoptosis through the sEV miR‐139‐5p/PDE4D axis. Therefore, we propose hUCMSC‐BAL as a therapeutic strategy for patients with early ALF.